Suzhou Sanegene Bio Inc.
Clinical trials sponsored by Suzhou Sanegene Bio Inc., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New obesity drug SGB-7342 enters first human safety trial Results expected Oct 2026 (estimated)
- Can a single injection drug calm the immune attack on kidneys? Results expected Dec 2026 (estimated)
- Can a new injection tame the blood cell destruction of PNH? Results expected Aug 2027 (estimated)
-
Can a new injection tame the blood cell destruction of PNH?
Disease control Not yet recruitingThis Phase II trial tests an experimental drug called SGB-9768 in adults with paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder where red blood cells break apart too early. The study gives the drug by injection under the skin and measures how well it lowers a marke…
Phase 2 • Sponsor: Suzhou Sanegene Bio Inc. • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New obesity drug SGB-7342 enters first human safety trial
Disease control Not yet recruitingThis early-stage study tests a single dose of an investigational drug called SGB-7342 in 45 adults who have obesity or are overweight. The main goal is to check if the drug is safe and tolerable. Researchers will also measure how the drug moves in the body and any weight changes.…
Phase 1 • Sponsor: Suzhou Sanegene Bio Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC